You are here

High throughput tau oligomer drug screening assay for Alzheimer's disease

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43GM108378-01
Agency Tracking Number: R43GM108378
Amount: $349,219.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIGMS
Solicitation Number: PA12-088
Timeline
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
665 N RIVERPOINT BLVD, STE 456
SPOKANE, WA 99202-1648
United States
DUNS: 78498897
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DAVID VACHON
 (509) 210-0736
 djvachon@iasismolecular.com
Business Contact
 DAVID VACHON
Phone: (509) 210-0736
Email: DJVACHON@IASISMOLECULAR.COM
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Three novel uncharged silver microbicides have been shown to be effective against a wide variety of pathogens have been shown to spontaneously form amorphous hydrogels when combined with glutathione will be formulated into two different ointment formulations and tested in an infected burn wound model in the rat. Formulation of the silver microbicides will be conducted at different concentrations for evaluation. The major specific aims of the proposed research involve thepreparation and formulation/processing of the silver microbicides, determination of antimicrobial capacity, cyto-compatability, and evaluation in an infected burn wound model in the rat. The primary objectives of the proposed therapy are: 1) resolution of infection, 2) improvement of healing, and 3. reduction in overall oxidative stress. This innovative and rational approach to a topical antimicrobial therapy is founded on the basis of several different studies that have revealed promising bioapplicable attributes of these silver microbicide complexes. The end-goal of this project is to enable the next phase of development of one or more of these novel microbicidal formulations that will be targeted for the treatment of burn wounds while developing a greater understanding of the mechanisms by which these compounds work. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Infection is the most common and most serious complication of a major burn injury. Despite improvements in burn wound management and antimicrobial therapy technologies, sepsis related to the burn accounts for 50-60% of deaths in burn patients today. Other complicating issues that hamper efficient healing include cellular oxidative stress, topical agent toxicity, and ease of patient treatment. An antimicrobial gel with minimal toxicity, good efficacy against relevant burn pathogens, anti oxidative characteristics, and soothing and hydrating properties, allows for easy visualization of the wound, and is easily cleaned from the patient is proposed as a solution to the aforementioned complications of burn injury.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government